Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy
- PMID: 3349601
Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy
Abstract
Water-suppressed proton nuclear magnetic resonance spectra were generated (by using 360 and 500 MHz systems) from human plasma and serum samples taken from 35 apparently healthy individuals, 52 patients with overt malignancies, and 37 patients with hypertriglyceridemia (triglycerides greater than 200 mg/dL or 2.26 mmol/L). The line widths from the lipoprotein-lipid methylene and methyl resonances at approximately 1.3 and 0.9 ppm were averaged by the method of Fossel et al. (N Engl J Med 1986;315:1369-76), but, contrary to their findings, we were unable to distinguish normal individuals from those with malignant tumors (e.g., mean +/- SD line width at 360 MHz: normal group = 32.9 +/- 3.6 Hz, malignant group = 28.3 +/- 4.9 Hz). The average line-width measurements (y), however, varied with the triglyceride content (x, mg/dL) of the plasma or serum as follows (logarithmic transformation of the data determined at 360 MHz and regression analysis): y = 110 (x-0.27). Data from both nonmalignant and malignant specimens fit this equation, the coefficient of correlation being -0.91. These findings suggest that considerable caution should be used in interpreting water-suppressed proton NMR spectra for cancer detection.
Similar articles
-
Detection of malignant tumors: water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.Magn Reson Med. 1987 Oct;5(4):395-7. doi: 10.1002/mrm.1910050414. Magn Reson Med. 1987. PMID: 3683172
-
[H-NMR spectroscopy of plasma cannot be used for cancer screening].Bull Cancer. 1988;75(8):795-800. Bull Cancer. 1988. PMID: 3179513 French.
-
Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors.N Engl J Med. 1990 Apr 5;322(14):953-8. doi: 10.1056/NEJM199004053221403. N Engl J Med. 1990. PMID: 2314447
-
The NMR blood test for cancer: current status.Cancer Cells. 1991 May;3(5):173-82. Cancer Cells. 1991. PMID: 1654067 Review.
-
Magnetic resonance spectroscopy in cancer research.Can Assoc Radiol J. 1990 Feb;41(1):32-8. Can Assoc Radiol J. 1990. PMID: 2178730 Review.
Cited by
-
Nuclear magnetic resonance spectroscopy of plasma to distinguish between malignant and benign diseases causing jaundice and cholestasis.J Cancer Res Clin Oncol. 1993;119(10):622-6. doi: 10.1007/BF01372726. J Cancer Res Clin Oncol. 1993. PMID: 8335681 Free PMC article.
-
C-13 NMR spectroscopy of plasma reduces interference of hypertriglyceridemia in the H-1 NMR detection of malignancy. Application in patients with breast lesions.Breast Cancer Res Treat. 1991 May;18(2):99-110. doi: 10.1007/BF01980972. Breast Cancer Res Treat. 1991. PMID: 1912613 Clinical Trial.
-
Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy.Breast Cancer Res Treat. 1995;36(3):287-97. doi: 10.1007/BF00713400. Breast Cancer Res Treat. 1995. PMID: 8573711
-
Failure to detect early breast cancer using in vitro nuclear magnetic resonance spectroscopy of plasma.Br J Cancer. 1993 Aug;68(2):389-92. doi: 10.1038/bjc.1993.346. Br J Cancer. 1993. PMID: 8347495 Free PMC article.
-
The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy.J Clin Exp Hepatol. 2017 Jun;7(2):83-92. doi: 10.1016/j.jceh.2017.03.007. Epub 2017 Mar 15. J Clin Exp Hepatol. 2017. PMID: 28663670 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources